3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
8
Cholangiocarcinoma
4
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Ovarian Neoplasms
2
Gallbladder Neoplasms
2
Colonic Neoplasms
2
Adenocarcinoma Of Esophagus
2
Rectal Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Basal Cell
1
Bile Duct Neoplasms
1
Interventions
Specimen Handling
3
Oxaliplatin
3
Leucovorin
3
durvalumab
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Folfox protocol
2
Fluorouracil
2
Cisplatin
2
Biopsy
2
zanidatamab
1
peposertib
1
pembrolizumab
1
dehydroftorafur
1
binimetinib
1
avelumab
1
Radiation Dose Hypofractionation
1
Radiation
1
Paclitaxel
1
Nivolumab
1
Irinotecan
1
Ipilimumab
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
Folfox protocol
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts
NCT07265674
2026-05-14
Beacon-BTC
J-Pharma Co., Ltd.
Phase 3
Recruiting
480 enrolled